Novo Nordisk A/S (NVO · NYSE)

Novo Nordisk shares have fallen 21.4% over the past month to $37.32, leaving the stock down 38.9% from its 52-week high with an RSI of 21, even as the FDA extended its review of the hemophilia drug denecimig over facility remediation issues. Fundamentals remain strong on profitability — 82.0% gross margin, 42.5% operating margin, and 59.8% ROE — but earnings fell 20.6% year over year on modest 2.1% revenue growth, and the latest quarter showed sequential revenue decline to $78.49B from $96.82B. The company beat estimates in three of its last four quarters, including the most recent ($0.96 vs. $0.82), and trades at a 9.4 P/E with a $164.79B market cap. Positive pipeline news included Wegovy data showing normalized liver fat in roughly 90% of trial participants and plans to launch oral obesity drugs in India in the first half of 2027.